Threat of Independent Payment Advisory Board action to lower drug spending in Medicare alleviated for another year. Estimated spending growth in the program does not reach targets that would prompt cuts.
Spending in the Medicare program is expected to stay within targets set by the Affordable Care Act over the next few years, avoiding the need for the Independent Payment Advisory Board or HHS to develop a plan this year for reducing costs in the program starting in 2019.
"Because the projected five-year Medicare per capita growth rate does not exceed the Medicare per capita target growth rate, there...
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
New rules requiring more granular drug pricing data to be disclosed in machine-readable files will go into effect in 2026.
The budget reconciliation bill nears final passage without pharmacy benefit manager reforms or provisions that would facilitate access to cell and gene therapies for children, but its Medicaid cuts pose a significant threat to prescription drug access.
